280 related articles for article (PubMed ID: 26871946)
1. ERβ decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function.
Bado I; Nikolos F; Rajapaksa G; Gustafsson JÅ; Thomas C
Oncotarget; 2016 Mar; 7(12):13599-611. PubMed ID: 26871946
[TBL] [Abstract][Full Text] [Related]
2. Estrogen Receptor Beta 1: A Potential Therapeutic Target for Female Triple Negative Breast Cancer.
Dey P; Wang A; Ziegler Y; Kumar S; Yan S; Kim SH; Katzenellenbogen JA; Katzenellenbogen BS
Endocrinology; 2022 Oct; 163(12):. PubMed ID: 36251879
[TBL] [Abstract][Full Text] [Related]
3. ERbeta1 represses basal breast cancer epithelial to mesenchymal transition by destabilizing EGFR.
Thomas C; Rajapaksa G; Nikolos F; Hao R; Katchy A; McCollum CW; Bondesson M; Quinlan P; Thompson A; Krishnamurthy S; Esteva FJ; Gustafsson JÅ
Breast Cancer Res; 2012 Nov; 14(6):R148. PubMed ID: 23158001
[TBL] [Abstract][Full Text] [Related]
4. P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.
Shapira I; Lee A; Vora R; Budman DR
Crit Rev Oncol Hematol; 2013 Nov; 88(2):284-92. PubMed ID: 23755891
[TBL] [Abstract][Full Text] [Related]
5. NUMB negatively regulates the epithelial-mesenchymal transition of triple-negative breast cancer by antagonizing Notch signaling.
Zhang J; Shao X; Sun H; Liu K; Ding Z; Chen J; Fang L; Su W; Hong Y; Li H; Li H
Oncotarget; 2016 Sep; 7(38):61036-61053. PubMed ID: 27506933
[TBL] [Abstract][Full Text] [Related]
6. ERβ1 inversely correlates with PTEN/PI3K/AKT pathway and predicts a favorable prognosis in triple-negative breast cancer.
Wang J; Zhang C; Chen K; Tang H; Tang J; Song C; Xie X
Breast Cancer Res Treat; 2015 Jul; 152(2):255-69. PubMed ID: 26070269
[TBL] [Abstract][Full Text] [Related]
7. ERβ1 inhibits metastasis of androgen receptor-positive triple-negative breast cancer by suppressing ZEB1.
Song W; Tang L; Xu Y; Sun Q; Yang F; Guan X
J Exp Clin Cancer Res; 2017 Jun; 36(1):75. PubMed ID: 28583190
[TBL] [Abstract][Full Text] [Related]
8. Agonists and knockdown of estrogen receptor β differentially affect invasion of triple-negative breast cancer cells in vitro.
Schüler-Toprak S; Häring J; Inwald EC; Moehle C; Ortmann O; Treeck O
BMC Cancer; 2016 Dec; 16(1):951. PubMed ID: 28003019
[TBL] [Abstract][Full Text] [Related]
9. FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells.
Taliaferro-Smith L; Oberlick E; Liu T; McGlothen T; Alcaide T; Tobin R; Donnelly S; Commander R; Kline E; Nagaraju GP; Havel L; Marcus A; Nahta R; O'Regan R
Oncotarget; 2015 Mar; 6(7):4757-72. PubMed ID: 25749031
[TBL] [Abstract][Full Text] [Related]
10. Modulation of Mitochondrial ERβ Expression Inhibits Triple-Negative Breast Cancer Tumor Progression by Activating Mitochondrial Function.
Song IS; Jeong YJ; Jeong SH; Kim JE; Han J; Kim TH; Jang SW
Cell Physiol Biochem; 2019; 52(3):468-485. PubMed ID: 30873822
[TBL] [Abstract][Full Text] [Related]
11. Silencing of ASPP2 promotes the proliferation, migration and invasion of triple-negative breast cancer cells via the PI3K/AKT pathway.
Wu T; Song H; Xie D; Zhao B; Xu H; Wu C; Hua K; Deng Y; Ji C; Hu J; Fang L
Int J Oncol; 2018 Jun; 52(6):2001-2010. PubMed ID: 29568874
[TBL] [Abstract][Full Text] [Related]
12. Elevated TGF-β1 and -β2 expression accelerates the epithelial to mesenchymal transition in triple-negative breast cancer cells.
Kim S; Lee J; Jeon M; Nam SJ; Lee JE
Cytokine; 2015 Sep; 75(1):151-8. PubMed ID: 26088755
[TBL] [Abstract][Full Text] [Related]
13. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor β selective agonists reduce invasiveness of triple-negative breast cancer cells.
Hinsche O; Girgert R; Emons G; Gründker C
Int J Oncol; 2015 Feb; 46(2):878-84. PubMed ID: 25420519
[TBL] [Abstract][Full Text] [Related]
15. Estrogen Receptor β4 Regulates Chemotherapy Resistance and Induces Cancer Stem Cells in Triple Negative Breast Cancer.
Bano A; Stevens JH; Modi PS; Gustafsson JÅ; Strom AM
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982940
[TBL] [Abstract][Full Text] [Related]
16. Cardamonin, a chalcone, inhibits human triple negative breast cancer cell invasiveness by downregulation of Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.
Shrivastava S; Jeengar MK; Thummuri D; Koval A; Katanaev VL; Marepally S; Naidu VGM
Biofactors; 2017 Mar; 43(2):152-169. PubMed ID: 27580587
[TBL] [Abstract][Full Text] [Related]
17. ERβ Sensitizes NSCLC to Chemotherapy by Regulating DNA Damage Response.
Nikolos F; Thomas C; Bado I; Gustafsson JÅ
Mol Cancer Res; 2018 Feb; 16(2):233-242. PubMed ID: 29117942
[TBL] [Abstract][Full Text] [Related]
18. Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells.
Krishnan SR; Nair BC; Sareddy GR; Roy SS; Natarajan M; Suzuki T; Peng Y; Raj G; Vadlamudi RK
Breast Cancer Res Treat; 2015 Apr; 150(3):487-99. PubMed ID: 25788226
[TBL] [Abstract][Full Text] [Related]
19. TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer.
Mukhopadhyay UK; Oturkar CC; Adams C; Wickramasekera N; Bansal S; Medisetty R; Miller A; Swetzig WM; Silwal-Pandit L; Børresen-Dale AL; Creighton CJ; Park JH; Konduri SD; Mukhopadhyay A; Caradori A; Omilian A; Bshara W; Kaipparettu BA; Das GM
J Natl Cancer Inst; 2019 Nov; 111(11):1202-1215. PubMed ID: 30990221
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells.
Wang ZT; Chen ZJ; Jiang GM; Wu YM; Liu T; Yi YM; Zeng J; Du J; Wang HS
Cell Signal; 2016 May; 28(5):506-515. PubMed ID: 26876786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
